GIM
VRTX icon

Generali Investments Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Generali Investments Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45M Buy
4,926
+1,560
+46% +$691K 0.53% 44
2026
Q1 		$1.5M Buy
3,366
+1,019
+43% +$475K 0.35% 60
2025
Q4 		$1.06M Buy
2,347
+550
+31% +$237K 0.21% 74
2025
Q3 		$704K Buy
+1,797
New +$751K 0.15% 94

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
SMDAM
Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.5B AUM 37.68% 1-Year Est. Return

Generali Investments Management's VRTX Position: Q2 2026 in Review

Generali Investments Management increased its Vertex Pharmaceuticals (VRTX) stake by 46% in Q2 2026, buying an estimated $691K and bringing the position to 4,926 shares worth $2.45M. The position accounts for 0.53% of the portfolio, ranked #44.

Generali Investments Management first reported a position in VRTX in Q3 2025 and has held it in 4 quarters since. 338 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Generali Investments Management held 4,926 shares of Vertex Pharmaceuticals worth $2.45M as of Q2 2026.
  • Generali Investments Management bought 1,560 Vertex Pharmaceuticals shares in Q2 2026, an estimated $691K.
  • Vertex Pharmaceuticals made up 0.53% of Generali Investments Management's portfolio in Q2 2026, its #44 holding.
  • Generali Investments Management first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 338 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Generali Investments Management's 13F filing for Q2 2026, filed 10 Jul 2026.